Selecting a Subcutaneous ICD for Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition in which sudden cardiac death (SCD) risk varies substantially between individuals. Ventricular tachyarrhythmias may occur in patients with severe hypertrophy, myocardial fibrosis, apical aneurysm, reduced systolic function, or a history of unexplained syncope. An implantable cardioverter-defibrillator (ICD) can reduce the risk of fatal ventricular arrhythmia, yet choosing the right system requires more than deciding whether an ICD is indicated.
A subcutaneous ICD (S-ICD) offers defibrillation without an intravascular lead. This feature is attractive for many younger patients with HCM, who may face decades of lead-related complications, venous obstruction, infection, and repeated procedures. The system has important limitations, however. It cannot provide conventional bradycardia pacing, cardiac resynchronization therapy, or antitachycardia pacing (ATP).
Selection therefore depends on two linked decisions: whether the patient has sufficient SCD risk to justify an ICD, and whether a shock-only system can safely meet the patient’s clinical needs. Careful rhythm evaluation, imaging, device screening, and shared decision-making are essential.
Establishing the indication for defibrillator therapy
The first step is an individualized assessment of SCD risk rather than an automatic preference for a particular device. A previous cardiac arrest or documented sustained ventricular tachycardia is a strong secondary-prevention indication. In primary prevention, clinicians consider established risk markers such as a family history of HCM-related SCD, unexplained or suspected cardiac syncope, marked left ventricular hypertrophy, nonsustained ventricular tachycardia, an apical aneurysm, left ventricular ejection fraction below 50%, and extensive late gadolinium enhancement on cardiac magnetic resonance imaging.
Risk markers do not carry identical weight in every patient. Age, competing illness, quality of life, exercise habits, arrhythmia burden, and the reliability of the clinical history should influence the discussion. A formal HCM risk calculator may support the assessment, but it should not replace expert interpretation, particularly in children, young adults, patients with apical disease, or those with newer imaging markers.
The decision should be revisited over time. HCM phenotype can evolve, and a patient who initially has a low estimated risk may later develop an apical aneurysm, reduced ejection fraction, increasing fibrosis, or more frequent ventricular arrhythmias. Serial echocardiography, ambulatory monitoring, and periodic clinical review help keep device decisions aligned with current risk.
When an S-ICD fits the clinical profile
An S-ICD is most suitable when a patient has a clear indication for defibrillation but no current requirement for chronic pacing. This includes many young people with HCM who have intact atrioventricular conduction, no symptomatic bradycardia, and no established need for ATP. Avoiding a transvenous lead can be particularly valuable when long-term lead survival, venous access, or infection risk is a major concern.
The system may also be considered in patients with limited venous access, prior device infection, congenital heart disease, or a strong preference to avoid an intravascular lead. Its extravascular design reduces exposure to some lead-associated complications, although it does not eliminate procedural infection, inappropriate shocks, generator replacement, or lead failure.
A key limitation is the absence of ATP. Some patients with HCM develop monomorphic ventricular tachycardia that can be terminated painlessly by ATP before a shock is required. If sustained monomorphic VT is documented or strongly anticipated, a transvenous ICD may offer a more appropriate treatment strategy. Likewise, a patient with progressive conduction disease, significant sinus node dysfunction, or likely future pacing needs may be better served by a system capable of pacing.
Anatomical and electrical screening before implantation
S-ICD screening is more demanding in HCM because hypertrophy, abnormal repolarization, bundle branch block, atrial enlargement, and scar can produce large or changing QRS-T complexes. The device must distinguish ventricular depolarization from the T wave. Failure of this distinction can result in T-wave oversensing and inappropriate shocks.
Pre-implant screening evaluates the available sensing vectors, commonly in more than one posture. Screening in both supine and upright positions is important because amplitude and morphology may change with posture. Exercise testing can reveal rate-related changes that are absent during resting assessment. Patients with marked electrocardiographic abnormalities should be assessed carefully rather than assumed to be suitable because of an acceptable resting tracing.
Lead and generator placement also matter. The generator is usually positioned laterally, while the subcutaneous lead is placed parallel to the sternum. Body habitus, chest shape, prior surgery, pectus deformity, and severe left ventricular enlargement can affect signal quality and the defibrillation field. Implantation should follow validated positioning and testing protocols, with attention to shock efficacy and the possibility of future revisions.
Comparing device capabilities and trade-offs
The choice between an S-ICD and a transvenous ICD should reflect the patient’s anticipated rhythm needs, not simply the desire to avoid an intravascular lead. The following comparison can structure the consultation:
| Clinical consideration | Subcutaneous ICD | Transvenous ICD |
|---|---|---|
| Ventricular fibrillation or fast VT termination | Effective defibrillation therapy | Effective defibrillation therapy |
| Bradycardia pacing | Generally unavailable, apart from limited post-shock support | Available when programmed |
| Antitachycardia pacing | Unavailable | Available |
| Cardiac resynchronization | Unavailable | Available with a suitable CRT system |
| Intravascular lead complications | Avoided | Lead fracture, venous obstruction, and endovascular infection are possible |
| Inappropriate shock mechanisms | T-wave oversensing, oversensing of signals, or supraventricular rhythms | Oversensing, lead noise, and supraventricular rhythms |
| Typical role in HCM | Defibrillation protection without pacing needs | Defibrillation with pacing or ATP requirements |
This comparison is especially relevant in HCM because a patient’s substrate may change. A young patient can begin with normal conduction and later develop atrioventricular block or atrial arrhythmias requiring additional treatment. The anticipated duration of device therapy should therefore be part of the initial decision.
Subcutaneous systems may reduce some long-term lead complications, but they can involve larger pockets and may deliver shocks for rhythms that a transvenous system could terminate with ATP. Device choice should balance the likelihood of those events against the risks associated with a transvenous lead. Neither approach is universally safer for every patient.
Situations requiring particular caution
Patients with a prior pacemaker, CRT device, or an indication for permanent pacing are generally poor candidates for an S-ICD alone. The same concern applies to documented sustained monomorphic VT that is likely to respond to ATP. In selected cases, a separate pacing strategy or a newer extravascular approach may be considered, but these decisions require specialized expertise and should not be treated as routine substitutions.
Atrial fibrillation and frequent supraventricular tachycardia also deserve attention. The S-ICD uses rate and morphology-based discrimination, and rapid atrial arrhythmias may trigger inappropriate therapy. Optimizing medical treatment, assessing the burden of atrial arrhythmia, and programming the device with appropriate detection zones can reduce this risk. Electrophysiology consultation is useful when the rhythm diagnosis is uncertain.
Perioperative planning is another practical issue. Electrocautery, changes in sensing, external defibrillation, and temporary deactivation of tachytherapy require a documented plan. Guidance on perioperative arrhythmia management can help clinicians coordinate device interrogation, magnet use, monitoring, and postoperative reactivation for noncardiac procedures.
Shared decision-making and follow-up
The consultation should explain what an S-ICD can do, what it cannot do, and what a shock may feel like. Patients should understand that the device treats dangerous ventricular rhythms but does not prevent HCM progression, eliminate atrial fibrillation, or replace medication and clinical surveillance. Driving restrictions, exercise, employment, device checks, and remote monitoring should be discussed before implantation.
Follow-up includes wound assessment, interrogation, battery surveillance, review of stored episodes, and evaluation after any shock. New syncope, palpitations, worsening heart failure symptoms, or repeated nonsustained VT may change the risk assessment. Inappropriate shocks should prompt a structured review of sensing, rhythm diagnosis, programming, and lead or generator position.
Clinicians and trainees can place these decisions within broader electrophysiology evidence by exploring the journal’s special issue collections, where research and reviews address defibrillation, HCM, device therapy, and arrhythmia management. Evidence should be interpreted alongside local guidelines, institutional experience, and the patient’s values.
Practical points for device selection
- Confirm the ICD indication using clinical history, imaging, rhythm monitoring, and individualized HCM risk assessment.
- Exclude a current or foreseeable need for bradycardia pacing, CRT, or ATP before choosing an S-ICD.
- Perform multi-vector ECG screening in different postures and consider exercise testing when repolarization abnormalities are present.
- Evaluate body habitus, chest anatomy, prior surgery, venous access, and the feasibility of reliable lead and generator positioning.
- Discuss inappropriate shocks, future pacing needs, procedural risks, follow-up responsibilities, and the patient’s preferences.
For clinicians managing HCM, the most defensible device choice is the one that matches both the patient’s arrhythmic risk and the treatment capabilities they may need over time. The Journal of Arrhythmia provides open-access research, guidelines, reviews, and educational material to support continuing practice in cardiac electrophysiology. Use current evidence and multidisciplinary discussion to make S-ICD selection a deliberate part of comprehensive HCM care.